Non-steroidal agents as 5-alpha reductase inhibitors
CA 2074539 A1 · Owner: Merck & Co. Inc. · Inventors: Witzel, Bruce E.; Tolman, Richard L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described are new non-steroidal drugs, for treatment of benign prostatic hyperplasia and other disorders mediated by high 5-alpha reductase activity, high dihydrotestosterone levels and other, conditions of hyperandrogenic stimulation of the, formula:, wherein, A is an 1,2-disubstituted aromatic ring selected from (a) benzene, naphthalene;, F3, 180/RJN118 - ii - 182; 181/RJN119, (b) 5-6 membered heteroaromatic ring containing, 1-2 N atoms, 1 S or O atom or combination, thereof;, D and E are independently -COOH CONH2, CONHRb, COORb, SO2OH, SO2NH2, SO3OH -SSO2ONa, PH(O)(OH), P(O)(OH)2;, X is O S, SO, or SO2:, R is H, C1-C4 alkyl. phenyl or substituted phenyl halo, haloalkyl, hydroxy, carboxy, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 23, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 23, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 23, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.